{"id":"https://openalex.org/W7204462866","doi":"https://doi.org/10.4018/979-8-3693-9276-8.ch004","title":"Antiviral Drug Discovery in Emerging Economics","display_name":"Antiviral Drug Discovery in Emerging Economics","publication_year":2025,"publication_date":"2025-05-28","ids":{"openalex":"https://openalex.org/W7204462866","doi":"https://doi.org/10.4018/979-8-3693-9276-8.ch004"},"language":"ng","primary_location":{"id":"doi:10.4018/979-8-3693-9276-8.ch004","doi":"https://doi.org/10.4018/979-8-3693-9276-8.ch004","is_oa":false,"landing_page_url":"https://doi.org/10.4018/979-8-3693-9276-8.ch004","pdf_url":null,"source":{"id":"https://openalex.org/S4306463409","display_name":"IGI Global eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320424","host_organization_name":"IGI Global","host_organization_lineage":["https://openalex.org/P4310320424"],"host_organization_lineage_names":["IGI Global"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Global Perspectives on Antiviral Drug Development","raw_type":"book-chapter"},"volume":{"id":"https://openalex.org/W7204491437","display_name":"Global Perspectives on Antiviral Drug Development"},"type":"book-chapter","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011050334","display_name":"Abhiruj Navabhatra","orcid":"https://orcid.org/0000-0003-4129-1302","observed_orcids":["https://orcid.org/0000-0003-4129-1302"]},"institutions":[{"id":"https://openalex.org/I89226531","display_name":"Rangsit University","ror":"https://ror.org/01cqcrc47","country_code":"TH","type":"education","lineage":["https://openalex.org/I89226531"]}],"countries":["TH"],"is_corresponding":false,"raw_author_name":"Abhiruj Navabhatra","raw_affiliation_strings":["College of Pharmacy, Rangsit University, Thailand"],"raw_orcid":"https://orcid.org/0000-0003-4129-1302","affiliations":[{"raw_affiliation_string":"College of Pharmacy, Rangsit University, Thailand","institution_ids":["https://openalex.org/I89226531"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5148464485","display_name":"Chonnipha Yangchaiya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I89226531","display_name":"Rangsit University","ror":"https://ror.org/01cqcrc47","country_code":"TH","type":"education","lineage":["https://openalex.org/I89226531"]}],"countries":["TH"],"is_corresponding":false,"raw_author_name":"Chonnipha Yangchaiya","raw_affiliation_strings":["College of Pharmacy, Rangsit University, Thailand"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"College of Pharmacy, Rangsit University, Thailand","institution_ids":["https://openalex.org/I89226531"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I89226531"],"apc_list":null,"apc_paid":null,"fwci":10.3213,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.98291695,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":95,"max":96},"biblio":{"volume":null,"issue":null,"first_page":"139","last_page":"174"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.36500000953674316,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T11792","display_name":"Pharmaceutical Economics and Policy","score":0.36500000953674316,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T14293","display_name":"Biotechnology and Related Fields","score":0.11500000208616257,"subfield":{"id":"https://openalex.org/subfields/1405","display_name":"Management of Technology and Innovation"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.08839999884366989,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antiviral-drug-discovery","display_name":"antiviral drug discovery","score":0.996999979019165},{"id":"https://openalex.org/keywords/emerging-infectious-diseases","display_name":"emerging infectious diseases","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.7749999761581421},{"id":"https://openalex.org/keywords/protacs","display_name":"PROTACs","score":0.9860000014305115},{"id":"https://openalex.org/keywords/nanotechnology-in-drug-delivery","display_name":"nanotechnology drug delivery","score":0.875},{"id":"https://openalex.org/keywords/rna-therapeutics","display_name":"RNA therapeutics","score":0.6570000052452087},{"id":"https://openalex.org/keywords/biomaterials","display_name":"biomaterials","score":0.9390000104904175},{"id":"https://openalex.org/keywords/neglected-diseases","display_name":"neglected diseases","score":0.5979999899864197},{"id":"https://openalex.org/keywords/public-private-partnerships","display_name":"public-private partnerships","score":0.8960000276565552},{"id":"https://openalex.org/keywords/drug-regulation","display_name":"drug regulation","score":0.6330000162124634},{"id":"https://openalex.org/keywords/capacity-building","display_name":"capacity building","score":0.871999979019165},{"id":"https://openalex.org/keywords/resource-limited-settings","display_name":"resource-limited settings","score":0.9150000214576721},{"id":"https://openalex.org/keywords/hiv","display_name":"HIV","score":0.8230000138282776},{"id":"https://openalex.org/keywords/hepatitis-c","display_name":"hepatitis C","score":0.8930000066757202},{"id":"https://openalex.org/keywords/covid-19","display_name":"COVID-19 pandemic","score":0.972000002861023}],"concepts":[{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.6057000160217285},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.4749999940395355},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4577000141143799},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.4325000047683716},{"id":"https://openalex.org/C121087249","wikidata":"https://www.wikidata.org/wiki/Q546395","display_name":"Emerging markets","level":2,"score":0.41260001063346863},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.3849000036716461},{"id":"https://openalex.org/C206345919","wikidata":"https://www.wikidata.org/wiki/Q20380951","display_name":"Resource (disambiguation)","level":2,"score":0.3686999976634979},{"id":"https://openalex.org/C2779756493","wikidata":"https://www.wikidata.org/wiki/Q846227","display_name":"Antiviral drug","level":3,"score":0.36579999327659607},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.3605000078678131},{"id":"https://openalex.org/C207267971","wikidata":"https://www.wikidata.org/wiki/Q120208","display_name":"Emerging technologies","level":2,"score":0.3402000069618225},{"id":"https://openalex.org/C64903051","wikidata":"https://www.wikidata.org/wiki/Q2198549","display_name":"Drug development","level":3,"score":0.33629998564720154},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.32739999890327454},{"id":"https://openalex.org/C3020491458","wikidata":"https://www.wikidata.org/wiki/Q131742","display_name":"Chronic hepatitis","level":3,"score":0.32589998841285706},{"id":"https://openalex.org/C46578552","wikidata":"https://www.wikidata.org/wiki/Q2725393","display_name":"Global health","level":3,"score":0.31540000438690186},{"id":"https://openalex.org/C55587333","wikidata":"https://www.wikidata.org/wiki/Q1133029","display_name":"Engineering ethics","level":1,"score":0.2922999858856201},{"id":"https://openalex.org/C83864248","wikidata":"https://www.wikidata.org/wiki/Q177323","display_name":"Developing country","level":2,"score":0.2847999930381775},{"id":"https://openalex.org/C3008058167","wikidata":"https://www.wikidata.org/wiki/Q84263196","display_name":"Coronavirus disease 2019 (COVID-19)","level":4,"score":0.28130000829696655},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.2734000086784363},{"id":"https://openalex.org/C3007834351","wikidata":"https://www.wikidata.org/wiki/Q82069695","display_name":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","level":5,"score":0.27320000529289246},{"id":"https://openalex.org/C2993777677","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Drug industry","level":2,"score":0.26460000872612},{"id":"https://openalex.org/C2778917124","wikidata":"https://www.wikidata.org/wiki/Q7309705","display_name":"Regulatory science","level":2,"score":0.2621999979019165},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.2597000002861023},{"id":"https://openalex.org/C3019038264","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug candidate","level":3,"score":0.25519999861717224},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.2517000138759613}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.4018/979-8-3693-9276-8.ch004","doi":"https://doi.org/10.4018/979-8-3693-9276-8.ch004","is_oa":false,"landing_page_url":"https://doi.org/10.4018/979-8-3693-9276-8.ch004","pdf_url":null,"source":{"id":"https://openalex.org/S4306463409","display_name":"IGI Global eBooks","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4310320424","host_organization_name":"IGI Global","host_organization_lineage":["https://openalex.org/P4310320424"],"host_organization_lineage_names":["IGI Global"],"type":"ebook platform"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Global Perspectives on Antiviral Drug Development","raw_type":"book-chapter"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.8048999905586243,"display_name":"Good health and well-being"},{"id":"https://metadata.un.org/sdg/17","score":0.5217000246047974,"display_name":"Partnerships for the goals"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":66,"referenced_works":["https://openalex.org/W2018978047","https://openalex.org/W3003442561","https://openalex.org/W3015647640","https://openalex.org/W3022605724","https://openalex.org/W3038661047","https://openalex.org/W3048872421","https://openalex.org/W3082017356","https://openalex.org/W3091276351","https://openalex.org/W3091405058","https://openalex.org/W3091993000","https://openalex.org/W3093070524","https://openalex.org/W3093168641","https://openalex.org/W3096046891","https://openalex.org/W3096717940","https://openalex.org/W3102201917","https://openalex.org/W3118294308","https://openalex.org/W3120287752","https://openalex.org/W3120640948","https://openalex.org/W3121509720","https://openalex.org/W3128640935","https://openalex.org/W3128880495","https://openalex.org/W3132968432","https://openalex.org/W3135540980","https://openalex.org/W3139099049","https://openalex.org/W3161036171","https://openalex.org/W3170648799","https://openalex.org/W3175729718","https://openalex.org/W3187055757","https://openalex.org/W3196548689","https://openalex.org/W3197130635","https://openalex.org/W3204961771","https://openalex.org/W3205393424","https://openalex.org/W4211238337","https://openalex.org/W4220712323","https://openalex.org/W4285251602","https://openalex.org/W4294876571","https://openalex.org/W4295211093","https://openalex.org/W4295250342","https://openalex.org/W4296766441","https://openalex.org/W4304687401","https://openalex.org/W4308129966","https://openalex.org/W4309503005","https://openalex.org/W4360983532","https://openalex.org/W4376277283","https://openalex.org/W4385621969","https://openalex.org/W4386167890","https://openalex.org/W4390064368","https://openalex.org/W4390886216","https://openalex.org/W4391237786","https://openalex.org/W4391251955","https://openalex.org/W4392127827","https://openalex.org/W4392563545","https://openalex.org/W4395688873","https://openalex.org/W4399123359","https://openalex.org/W4399481765","https://openalex.org/W4400269243","https://openalex.org/W4400280318","https://openalex.org/W4400402280","https://openalex.org/W4400586572","https://openalex.org/W4400767290","https://openalex.org/W4400929412","https://openalex.org/W4401105826","https://openalex.org/W4401667972","https://openalex.org/W4403681325","https://openalex.org/W4403842906","https://openalex.org/W4404695918"],"related_works":["https://openalex.org/W7204470294","https://openalex.org/W7139982254","https://openalex.org/W4410542930","https://openalex.org/W7170261098","https://openalex.org/W6931151784","https://openalex.org/W4396598889","https://openalex.org/W4413408373","https://openalex.org/W7162542356","https://openalex.org/W4241009071","https://openalex.org/W7155653165"],"abstract_inverted_index":{"Emerging":[0],"infectious":[1],"diseases":[2,89],"underscore":[3],"the":[4,105],"urgent":[5],"need":[6],"for":[7,25,29],"new":[8],"antiviral":[9,112],"drugs":[10],"because":[11],"of":[12,72],"their":[13],"significant":[14],"impact":[15],"on":[16],"global":[17],"health.":[18],"Although":[19],"important":[20],"advancements":[21],"such":[22,36,61],"as":[23,37,62,102],"HAART":[24],"HIV":[26],"and":[27,43,67,74,78,117,125],"DAAs":[28],"hepatitis":[30],"C":[31],"have":[32,97],"been":[33],"made,":[34],"challenges":[35,80,130],"drug":[38,49,75],"resistance,":[39],"limited":[40],"vaccine":[41],"effectiveness,":[42],"complex":[44],"regulatory":[45,79,123],"landscapes":[46],"persist.":[47],"Traditional":[48],"discovery":[50],"methods":[51],"are":[52,90],"resource":[53],"intensive,":[54],"prompting":[55],"a":[56],"shift":[57],"toward":[58],"innovative":[59,111],"techniques":[60],"PROTACs,":[63],"RIBOTACs,":[64],"CRISPR-based":[65],"strategies,":[66],"nanotechnologies,":[68],"which":[69],"address":[70,129],"issues":[71],"resistance":[73],"delivery.":[76],"Financial":[77],"remain":[81],"critical,":[82],"particularly":[83],"in":[84,131],"developing":[85],"countries":[86],"where":[87],"neglected":[88],"prevalent.":[91],"Collaborative":[92],"efforts,":[93],"including":[94,114],"public\u2012private":[95],"partnerships,":[96],"successfully":[98],"addressed":[99],"funding":[100],"gaps,":[101],"demonstrated":[103],"during":[104],"COVID-19":[106],"pandemic.":[107],"This":[108],"chapter":[109],"explores":[110],"approaches,":[113],"RNA-based":[115],"therapies":[116],"biomaterials,":[118],"while":[119],"emphasizing":[120],"sustainable":[121],"development,":[122],"reforms,":[124],"capacity":[126],"building":[127],"to":[128],"resource-limited":[132],"settings.":[133]},"counts_by_year":[{"year":2026,"cited_by_count":2}],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2026-08-28T00:00:00"}